First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients.

CONCLUSIONS: Our first-in-human results demonstrate the safety and feasibility of non-invasive in vivo detection of tumor epichaperomes using 124I-PU-H71 PET, supporting clinical development of PU-H71 and other epichaperome-targeted therapeutics.
PMID: 32366671 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 3, 2020 Category: Cancer & Oncology Authors: Dunphy MP, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, Hudis CA, Bromberg J, Schöder HM, Fox JJ, Zhang H, Chiosis G, Lewis JS, Larson Tags: Clin Cancer Res Source Type: research